DB:XE9

Stock Analysis Report

Executive Summary

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs.


Snowflake Analysis

Flawless balance sheet with acceptable track record.

Share Price & News

How has Xencor's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: XE9's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-10.2%

XE9

-4.1%

DE Biotechs

-5.7%

DE Market


1 Year Return

8.6%

XE9

3.7%

DE Biotechs

6.1%

DE Market

Return vs Industry: XE9 exceeded the German Biotechs industry which returned 3.7% over the past year.

Return vs Market: XE9 exceeded the German Market which returned 6.1% over the past year.


Shareholder returns

XE9IndustryMarket
7 Day-10.2%-4.1%-5.7%
30 Day-3.9%-8.2%-5.7%
90 Day-13.9%-2.0%-3.6%
1 Year8.6%8.6%4.0%3.7%9.3%6.1%
3 Year30.7%30.7%38.2%36.7%8.9%-0.7%
5 Year116.7%116.7%9.9%7.5%13.6%-2.0%

Price Volatility Vs. Market

How volatile is Xencor's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Xencor undervalued compared to its fair value and its price relative to the market?

67.5x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: XE9 (€29.8) is trading above our estimate of fair value (€21.49)

Significantly Below Fair Value: XE9 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: XE9 is poor value based on its PE Ratio (67.5x) compared to the Biotechs industry average (37.5x).

PE vs Market: XE9 is poor value based on its PE Ratio (67.5x) compared to the German market (20.2x).


Price to Earnings Growth Ratio

PEG Ratio: XE9's earnings are forecast to decline next year, so we can't calculate its PEG ratio.


Price to Book Ratio

PB vs Industry: XE9 is good value based on its PB Ratio (3.1x) compared to the DE Biotechs industry average (3.2x).


Next Steps

Future Growth

How is Xencor forecast to perform in the next 1 to 3 years based on estimates from 11 analysts?

-11.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: XE9's earnings are forecast to decline over the next 3 years (-11.8% per year).

Earnings vs Market: XE9's earnings are forecast to decline over the next 3 years (-11.8% per year).

High Growth Earnings: XE9's earnings are forecast to decline over the next 3 years.

Revenue vs Market: XE9's revenue (23.8% per year) is forecast to grow faster than the German market (5.1% per year).

High Growth Revenue: XE9's revenue (23.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if XE9's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Xencor performed over the past 5 years?

7.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: XE9 has high quality earnings.

Growing Profit Margin: XE9 became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: XE9 has become profitable over the past 5 years, growing earnings by 7.8% per year.

Accelerating Growth: XE9 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: XE9 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: XE9's Return on Equity (4.5%) is considered low.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Xencor's financial position?


Financial Position Analysis

Short Term Liabilities: XE9's short term assets ($558.4M) exceed its short term liabilities ($66.6M).

Long Term Liabilities: XE9's short term assets ($558.4M) exceed its long term liabilities ($10.5M).


Debt to Equity History and Analysis

Debt Level: XE9 is debt free.

Reducing Debt: XE9 had no debt 5 years ago.

Debt Coverage: XE9 has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: XE9 has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: XE9 has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if XE9's debt is covered by short term assets.


Next Steps

Dividend

What is Xencor's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.8%industryaverage1.0%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate XE9's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate XE9's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if XE9's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XE9's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of XE9's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.6yrs

Average management tenure


CEO

Bassil Dahiyat (49yo)

15yrs

Tenure

US$4,372,828

Compensation

Dr. Bassil I. Dahiyat, Ph.D. Co-founded Xencor, Inc. in August 1997 and has been its President and Chief Executive Officer since February 2005. Dr. Dahiyat served as Chief Executive Officer of Xencor from ...


CEO Compensation Analysis

Compensation vs Market: Bassil's total compensation ($USD4.37M) is above average for companies of similar size in the German market ($USD1.63M).

Compensation vs Earnings: Bassil's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Bassil Dahiyat
Co-Founder15yrsUS$4.37m0.61% $10.5m
John Kuch
Senior VP of Finance & CFO9.3yrsUS$1.86m0.13% $2.3m
John Desjarlais
Senior VP of Research & Chief Scientific Officer5.6yrsUS$1.92m0.15% $2.6m
Charles Liles
Associate Director and Head of Corporate Communications & Investor Relations0yrsno datano data
Celia Eckert
VP, General Counsel & Corporate Secretary0.4yrsno datano data
Allen Yang
Senior VP & Chief Medical Officer0.2yrsno datano data

5.6yrs

Average Tenure

55yo

Average Age

Experienced Management: XE9's management team is seasoned and experienced (5.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Bassil Dahiyat
Co-Founder15yrsUS$4.37m0.61% $10.5m
Richard Ranieri
Independent Director2.2yrsUS$232.87kno data
Richard Lerner
Member of Scientific Advisory Board0yrsno datano data
Alan Montgomery
Independent Director4.9yrsUS$273.66kno data
Yujiro Hata
Independent Director4.6yrsUS$235.13kno data
Kevin Gorman
Independent Director2.8yrsUS$231.38kno data
Jeffrey Ravetch
Member of Scientific Advisory Board10.7yrsno datano data
Ellen Feigal
Independent Director1.3yrsUS$409.76kno data
Kurt Gustafson
Independent Director5.6yrsUS$240.13kno data
Dagmar Rosa-Bjorkeson
Director0.2yrsno datano data

4.6yrs

Average Tenure

63yo

Average Age

Experienced Board: XE9's board of directors are considered experienced (4.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.8%.


Top Shareholders

Company Information

Xencor, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Xencor, Inc.
  • Ticker: XE9
  • Exchange: DB
  • Founded: 1997
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.890b
  • Listing Market Cap: US$1.737b
  • Shares outstanding: 56.72m
  • Website: https://www.xencor.com

Number of Employees


Location

  • Xencor, Inc.
  • 111 West Lemon Avenue
  • 2nd Floor
  • Monrovia
  • California
  • 91016
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
XNCRNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDDec 2013
XE9DB (Deutsche Boerse AG)YesCommon StockDEEURDec 2013

Biography

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The company’s product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; and XmAb7195, an immune inhibitor that has been completed Phase I clinical trial for the treatment of asthma and allergic diseases. Its product candidates also comprise XmAb14045, a bispecific oncology candidate, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; XmAb13676 that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers MOR208, an antibody drug that is in Phase III clinical trial to treat non-Hodgkin lymphomas, as well as in Phase II clinical trial for chronic lymphocytic leukemia; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG50, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, XmAb23104, and XmAb24306 which are in preclinical Phase. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; MorphoSys Ag; Amgen Inc.; and Catalent Pharma Solutions LLC. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/25 22:52
End of Day Share Price2020/02/25 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.